Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The Nordic Lymphoma Group (NLG) study in adult anaplastic large cell lymphoma

Francesco d'Amore • 4 Dec 2015
ASH 2015
T-Cell Lymphoma Etoposide

Francesco d’Amore, MD, PhD from Aarhus University, Aarhus, Denmark talks about the Nordic Lymphoma Group (NLG) study on the addition of etoposide to CHOP in adult anaplastic large cell lymphoma patients. Dr d’Amore discusses how the addition of etoposide improves the outcome of patients, as demonstrated by the Phase II clinical trial published in 2012 on the use of CHOEP bi-weekly followed by autologous transplant consolidation in young patients.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

More from Francesco d'Amore

Managing T-cell lymphomas in light of the updated WHO classification
7:22
Managing T-cell lymphomas in light of the updated WHO classification
Francesco d'Amore • 27 Sep 2019
Clinical trials, pathologies and developments in personalized medicine
16:57
Clinical trials, pathologies and developments in personalized medicine
Francesco d'Amore et al. • 18 Sep 2017
iwNHL 2017: T-cell lymphomas, Hodgkin's lymphoma, immunotherapy and epigenetics
iwNHL 2017: T-cell lymphomas, Hodgkin's lymphoma, immunotherapy and epigenetics
Francesco d'Amore et al. • 8 Sep 2017
Update of peripheral T-cell lymphoma treatment
6:49
Update of peripheral T-cell lymphoma treatment
Elaine Jaffe et al. • 5 Sep 2014

Related Videos

Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Transplant decision-making: ASCT versus alloSCT in T-cell lymphoma
1:54
Transplant decision-making: ASCT versus alloSCT in T-cell lymphoma
Mary Jo Lechowicz • 11 Sep 2026
Mechanistic insights into purinostat mesylate for treating hematologic malignancies
9:09
Mechanistic insights into purinostat mesylate for treating hematologic malignancies
Lijuan Chen • 30 May 2026
The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
2:37
The Phase II CHEPA trial: brentuximab vedotin, CHP, and etoposide in newly diagnosed CD30+ PTCL
Marek Trněný • 12 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals